Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
about
Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety dataThe current state of adverse event reporting in hemophilia.The safety of pharmacologic options for the treatment of persons with hemophilia.Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case reportQuantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyUtility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice.Clinical use of factor VIII and factor IX concentratesPharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Current management of hemophilia B: recommendations, complications and emerging issues.Interaction between VWF and FVIII in treating VWD.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.Safety surveillance in haemophilia and allied disorders.Future of haemophilia outcome assessment: registries are key to optimized treatment.Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.Joint surgery in von Willebrand disease: a multicentre cross-sectional study.Thromboprophylaxis and Outcomes for Total Joint Arthroplasty in Congenital Bleeding Disorders: A Single-Center Experience.The use of short-term central venous catheters for optimizing continuous infusion of coagulation factor concentrate in haemophilia patients undergoing major surgical procedures.Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013.Current and Emerging Options for the Management of Inherited von Willebrand Disease.Management of orthopaedic surgery in rare bleeding disorders.Orthopaedic surgery in patients with von Willebrand disease.Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.The development of pulmonary embolus in patients with haemophilia A and high-titre inhibitors - a case series and review of the literature.Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.Clotting factor concentrate use and occurrence of thrombotic events in patients with hemophilia: A nationwide and 15-year cohort study.Current challenges in the diagnosis and management of patients with inherited von Willebrand 's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.
P2860
Q26750402-E6BE8042-C507-47BF-AAFB-4FA651C6AF77Q30239952-7C853697-A021-43A2-8623-31CD2E7D52D0Q30249200-D678C6EB-12D2-41A8-9178-9961DFB3DD7FQ30491320-495A69C1-F937-4A75-99A1-AE2D1BFE4D23Q34183076-CEB2C8A3-393D-4639-83FD-823E81B35F0AQ34416394-5998EE58-BB03-4541-A93A-8461B80CD593Q35846930-7FCC58E8-B4E8-411D-AB9D-5CA932593C08Q37370356-BF1A6956-9124-451D-BEDB-86EB5527B439Q37645977-1E2239E1-D129-4FE7-A107-6D11B5BA6DFDQ38014345-D6620EA7-6488-4F34-9286-61CFFBF65138Q38227605-C6440282-FCF3-4B04-8565-33AD95F7C3ACQ38238972-BD575E5B-BAAC-46C2-8DF6-1818679B6780Q38326080-1E963872-6FE9-42A9-94EA-9422795696E3Q38720560-9F9E108A-D9BA-4ACD-B7FE-E3BAE74060A7Q38764214-AE500C06-FD6C-42B4-8857-4A7A53162B2EQ38784133-A06F4769-5617-4638-91D3-68FC7767D3D5Q38864911-EBBF2946-232F-4A67-819D-931B3D1AA87CQ38953180-2C8BA5D6-EF8A-4BF3-B1AC-7F1543617D81Q40341489-D6C1DE11-7331-4009-A74C-9065B502B943Q40705500-640D106B-E010-4B95-BF7E-3C0B4CCD96F9Q40930823-9BD252C4-E2A6-4484-B0B6-CF927107CC91Q41298252-A7FA8575-5D7E-4FA9-AFBB-69B4752EB6CAQ41620644-00247C89-2DEA-454D-8716-F0DBEC730DC6Q42232716-83B0F9D4-76A9-4760-8E8B-01637F95FC89Q44110513-A20B9016-73D8-4A21-B371-0B953883C3A1Q45867482-DB575D97-2720-4802-B43E-7B39CCDE411FQ45872658-3503B4A3-9031-4EB5-8686-A9C29B92730FQ45874429-FBE14555-0880-4860-B6CC-40240ADDBA04Q45884079-486B68EA-1851-41F3-BDC2-09B446A0787CQ48545948-565A6637-4756-47C4-9DC3-A5D11F4F3641
P2860
Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Thrombotic adverse events to c ...... review of prospective studies.
@en
Thrombotic adverse events to c ...... review of prospective studies.
@nl
type
label
Thrombotic adverse events to c ...... review of prospective studies.
@en
Thrombotic adverse events to c ...... review of prospective studies.
@nl
prefLabel
Thrombotic adverse events to c ...... review of prospective studies.
@en
Thrombotic adverse events to c ...... review of prospective studies.
@nl
P2093
P2860
P1433
P1476
Thrombotic adverse events to c ...... review of prospective studies
@en
P2093
E Santagostino
M Franchini
P M Mannucci
P2860
P304
P356
10.1111/J.1365-2516.2012.02758.X
P577
2012-02-15T00:00:00Z